Thorsten Lehr

The Effect of Dabigatran Plasma Concentrations and Patient Characteristics on the Frequency of Ischemic Stroke and Major Bleeding in Atrial Fibrillation Patients

Paul Reilly, Thorsten Lehr, Sebastian Haertter et al. · Journal of the American College of Cardiology · 2013 · 814 citations

Thrombosis, Dabigatran Plasma Concentrations, Ischemic Stroke +15

A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study

Jesse J. Swen, Cathelijne H. van der Wouden, Lisanne E. N. Manson et al. · The Lancet · 2023 · 462 citations · Full text

Drug Safety, Adverse Drug Reactions, Pharmacoepidemiology +9

A reference map of potential determinants for the human serum metabolome

Noam Bar, Tal Korem, Omer Weissbrod et al. · Nature · 2020 · 427 citations · Full text

Reference Map, Human Serum Metabolome, Medicine +11

Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: First results of a phase Ib/IIa study

Pavel Bogomolov, A. A. Alexandrov, M. V. Macievich et al. · Journal of Hepatology · 2016 · 380 citations

Chronic Hepatitis D, Hepatology, Viral Hepatitis +8

Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non‐valvular atrial fibrillation from the RE‐LY trial

Karl‐Heinz Liesenfeld, Thorsten Lehr, C. Dansirikul et al. · Journal of Thrombosis and Haemostasis · 2011 · 302 citations · Full text

Thrombosis, Cardiovascular Disease, Medicine +10